Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xtant Medical Holdings (XTNT) Cash from Operations (2016 - 2025)

Xtant Medical Holdings (XTNT) has disclosed Cash from Operations for 16 consecutive years, with 4612000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Cash from Operations rose 368.45% to 4612000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was 7831000.0, a 158.11% increase, with the full-year FY2024 number at 11896000.0, down 25.02% from a year prior.
  • Cash from Operations was 4612000.0 for Q3 2025 at Xtant Medical Holdings, up from 1276000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 4612000.0 in Q3 2025 to a low of 5755000.0 in Q1 2024.
  • A 5-year average of 1007736.84 and a median of 1004000.0 in 2022 define the central range for Cash from Operations.
  • Peak YoY movement for Cash from Operations: surged 955.87% in 2021, then tumbled 16906.67% in 2023.
  • Xtant Medical Holdings' Cash from Operations stood at 423000.0 in 2021, then crashed by 640.9% to 2288000.0 in 2022, then skyrocketed by 60.01% to 915000.0 in 2023, then soared by 172.68% to 665000.0 in 2024, then soared by 593.53% to 4612000.0 in 2025.
  • Per Business Quant, the three most recent readings for XTNT's Cash from Operations are 4612000.0 (Q3 2025), 1276000.0 (Q2 2025), and 1278000.0 (Q1 2025).